• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $VRNA

    Verona Pharma plc

    Subscribe to $VRNA
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: veronapharma.com

    Peers

    $KALV
    $MTP

    Recent Analyst Ratings for Verona Pharma plc

    DatePrice TargetRatingAnalyst
    4/28/2025$100.00Buy
    TD Cowen
    4/21/2025$80.00Overweight
    Cantor Fitzgerald
    1/10/2025$68.00Buy
    ROTH MKM
    10/3/2024$50.00Overweight
    Wells Fargo
    5/22/2023$35.00 → $38.00Buy
    Jefferies
    9/19/2022$27.00Outperform
    Wedbush
    8/26/2022$31.00Overweight
    Piper Sandler
    11/12/2021$18.00 → $23.00Buy
    Canaccord Genuity
    9/13/2021$25.00Buy
    HC Wainwright & Co.
    See more ratings

    Verona Pharma plc Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verona Pharma Announces June 2025 Investor Conference Participation

      LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com. For further information please

      5/21/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

      Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease ("COPD"), two from nonclinical studies, and one from a real-world data analysis, will be presented at the American Thoracic Society Conference ("ATS") 2025. The posters are published on the ATS website an

      5/6/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

      4/29/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

      4/15/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Announces Changes to Its Board of Directors

      Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy. In addition, John Schmid has decided not to stand for re-election at the Company's 2025 Annual Stockholders Meeting, at which time the size of the Board will be reduced to eight members. "I am honored to welcome Jim to our Board of Direc

      3/28/25 8:00:00 AM ET
      $VRNA
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

      RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement ("RIPSA") and increasing the debt facility to $450 million on improved terms with funds managed by Oaktree Capital Management, L.P. ("Oaktree") and OMERS Life Sciences ("OMERS") announced in May 2024. "We are pleased that Oaktree and OMERS recog

      3/28/25 7:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provide

      2/27/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Announces March 2025 Investor Conference Participation

      LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45th Annual Health Care ConferenceDate: Monday, March 3, 2025Time: 11:10 a.m. ET / 4:10 p.m. GMTLocation: Boston, MA Leerink Partners 2025 Global Healthcare ConferenceDate: Monday, March 10, 2025Time: 8:40 a.m. ET / 1:40 p.m. GMTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com. For further information please co

      2/18/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-836-8184 for callers in the United States+1-646-357-8785 for international callers A live webcast will be available on the Events and Presentations link on the Investors p

      2/13/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

      Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions filled in 2024 across a broad COPD population Approximately 45% of Tier 1 HCPs prescribed Ohtuvayre LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces preliminary unaudited net product sales for the fourth quarter and full year ended December 31, 2024, and provides a corporate update. "2024 was another transformational year for Verona with the appro

      1/7/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verona Pharma plc Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 5:46:11 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:50:28 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Verona Pharma plc

      SC 13G - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:31:56 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 9:47:59 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/13/24 8:46:02 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/12/24 10:34:15 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Verona Pharma plc

      SC 13D/A - Verona Pharma plc (0001657312) (Subject)

      8/28/24 9:51:34 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Verona Pharma plc

      SC 13G - Verona Pharma plc (0001657312) (Subject)

      7/29/24 9:43:57 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Verona Pharma plc

      SC 13G - Verona Pharma plc (0001657312) (Subject)

      7/12/24 4:04:11 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Verona Pharma plc (Amendment)

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      2/14/24 5:01:36 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verona Pharma plc Leadership Updates

    Live Leadership Updates

    See more
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

      ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update. "The first quarter of 2021 set a positive tone for what we expect to be another exciting year of substantial progress for Verona Pharma," said David Zaccardelli, Pharm. D., President and Chief E

      4/29/21 2:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verona Pharma plc Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Hahn Mark W sold $3,733,944 worth of Ordinary Shares (400,000 units at $9.33), decreasing direct ownership by 3% to 12,678,992 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/29/25 4:16:57 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zaccardelli David sold $3,734,579 worth of Ordinary Shares (400,000 units at $9.34), decreasing direct ownership by 3% to 13,590,168 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/29/25 4:15:16 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sinha Vikas exercised 160,000 units of Ordinary Shares at a strike of $0.50 and sold $1,502,928 worth of Ordinary Shares (160,000 units at $9.39) (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/22/25 4:06:12 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Sinha Vikas exercised 160,000 units of Ordinary Shares at a strike of $1.40 and sold $1,427,328 worth of Ordinary Shares (160,000 units at $8.92) (SEC Form 4)

      4/A - Verona Pharma plc (0001657312) (Issuer)

      5/22/25 4:05:12 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Fisher Andrew sold $685,600 worth of Ordinary Shares (80,000 units at $8.57) and exercised 80,000 units of Ordinary Shares at a strike of $2.11 (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/16/25 4:31:28 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ackermann Christina exercised 40,000 units of Ordinary Shares at a strike of $1.93 and sold $337,600 worth of Ordinary Shares (40,000 units at $8.44) (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/16/25 4:30:26 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Rickard Kathleen A. sold $1,014,343 worth of Ordinary Shares (114,984 units at $8.82), decreasing direct ownership by 4% to 2,546,472 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/8/25 4:30:16 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Rickard Kathleen A. sold $440,350 worth of Ordinary Shares (49,200 units at $8.95) and converted options into 50,000 units of Ordinary Shares, increasing direct ownership by 0.03% to 2,661,456 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/5/25 4:32:18 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Hahn Mark W sold $5,311,479 worth of Ordinary Shares (587,008 units at $9.05) and converted options into 200,000 units of Ordinary Shares, decreasing direct ownership by 3% to 13,078,992 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/5/25 4:31:33 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ebsworth David R exercised 140,000 units of Ordinary Shares at a strike of $1.93, increasing direct ownership by 10% to 1,476,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/5/25 4:30:54 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verona Pharma plc SEC Filings

    See more
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/27/25 4:33:47 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/27/25 4:31:13 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/20/25 4:30:55 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plc

      SCHEDULE 13G/A - Verona Pharma plc (0001657312) (Subject)

      5/15/25 4:49:13 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Verona Pharma plc

      SCHEDULE 13G - Verona Pharma plc (0001657312) (Subject)

      5/14/25 11:47:19 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/2/25 4:24:30 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/2/25 4:24:08 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      4/29/25 4:21:40 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Verona Pharma plc

      10-Q - Verona Pharma plc (0001657312) (Filer)

      4/29/25 8:53:25 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Verona Pharma plc (0001657312) (Filer)

      4/29/25 6:07:04 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verona Pharma plc Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/18/24 4:20:05 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/7/24 6:57:21 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/7/24 6:56:12 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ebsworth David R bought $103,320 worth of Ordinary Shares (36,000 units at $2.87), increasing direct ownership by 4% to 880,643 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      8/14/24 4:15:13 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edwards Martin bought $61,973 worth of Ordinary Shares (33,736 units at $1.84), increasing direct ownership by 30% to 144,800 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/22/23 5:09:08 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ebsworth David R bought $316,080 worth of Ordinary Shares (160,000 units at $1.98), increasing direct ownership by 23% to 844,643 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/8/23 4:15:10 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verona Pharma plc Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Verona Pharma with a new price target

      TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00

      4/28/25 8:38:21 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Verona Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $80.00

      4/21/25 8:39:43 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Verona Pharma with a new price target

      ROTH MKM initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $68.00

      1/10/25 8:44:57 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Verona Pharma with a new price target

      Wells Fargo initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $50.00

      10/3/24 7:43:08 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Verona Pharma with a new price target

      Jefferies resumed coverage of Verona Pharma with a rating of Buy and set a new price target of $38.00 from $35.00 previously

      5/22/23 8:58:04 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush resumed coverage on Verona Pharma with a new price target

      Wedbush resumed coverage of Verona Pharma with a rating of Outperform and set a new price target of $27.00

      9/19/22 7:45:47 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Verona Pharma with a new price target

      Piper Sandler initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $31.00

      8/26/22 7:21:27 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Verona Pharma with a new price target

      Canaccord Genuity reiterated coverage of Verona Pharma with a rating of Buy and set a new price target of $23.00 from $18.00 previously

      11/12/21 8:52:20 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Verona Pharma with a new price target

      HC Wainwright & Co. initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $25.00

      9/13/21 7:38:54 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Verona Pharma with a new price target

      Canaccord Genuity reiterated coverage of Verona Pharma with a rating of Buy and set a new price target of $18.00 from $19.00 previously

      5/3/21 10:18:33 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Verona Pharma plc Financials

    Live finance-specific insights

    See more
    • Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

      4/29/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

      4/15/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provide

      2/27/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-836-8184 for callers in the United States+1-646-357-8785 for international callers A live webcast will be available on the Events and Presentations link on the Investors p

      2/13/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

      Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter

      11/7/24 7:00:00 AM ET
      $AGEN
      $LGND
      $MRK
      $TAK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference call today at 9:00 a.m. ET / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2024, and provides a corporate update. "We are pleased to report an exceptionally strong st

      11/4/24 2:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-833-816-1396 for callers in the United States+1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Compan

      10/21/24 2:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2024, and provides a corporate update. "We are very pleased today to announce that Ohtuvayre (ensifentrine) is now available in the US for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") in adults," said David Zac

      8/8/24 2:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-833-816-1396 for callers in the United States+1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Company's

      7/25/24 2:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care